Guj. Themis Bio.

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE942C01045
NSEID: GUJTHEM
BSEID: 506879

INR

408.55

18.85 (4.84%)

BSENSE

Dec 19

BSE+NSE Vol: 8.71 lacs

{
  "main_header": {
    "sid": 925632,
    "name": "Guj. Themis Bio.",
    "stock_name": "Guj. Themis Bio.",
    "full_name": "Gujarat Themis Biosyn Ltd",
    "name_url": "stocks-analysis/guj-themis-bio",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "408.55",
    "chg": 18.85,
    "chgp": "4.84%",
    "dir": 1,
    "prev_price": "389.70",
    "mcapval": "4,240.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506879,
    "symbol": "GUJTHEM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE942C01045",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "8.71 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/guj-themis-bio-925632-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Guj. Themis Bio. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-themis-bio-fallingrising-3764313",
        "imagepath": "",
        "date": "2025-12-20 02:24:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Stock Performance Outshines Benchmarks</strong></p>\n<p>The recent price surge is underpinned by the company’s impressive track record relative to broader market indices. Over the past year, Gujarat Themis Biosyn has delivered a 32.00% return, significantly outperforming the Sensex’s 7.21% gain during the same period. Even more striking is the stock’s five-year return of 1087.67%, dwarfing the Sensex’s 80.85% growth. This exceptional long-term performance highlights the company’s ability to generate substantial shareholder value, which continues to attract investor confidence.</p>\n<p>In the short term, the stock has also shown resilience. Despite a one-month dip of 6.52%, it rebounded strongly in the past week with a 4.22% gain, while the Sensex declined by 0.40%. This recent recovery signals..."
      },
      {
        "title": "Guj. Themis Bio. Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/guj-themis-bio-downgraded-to-hold-by-marketsmojo-amid-valuation-concerns-3763748",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GujThemisBio_mojoScore_3763748.png",
        "date": "2025-12-19 10:10:20",
        "description": "Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, highlighting both strengths and challenges in its recent performance."
      },
      {
        "title": "Guj. Themis Bio. Sees Revision in Market Assessment Amid Valuation and Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/guj-themis-bio-downgraded-to-hold-by-marketsmojo-amid-valuation-concerns-3735226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujThemisBio_mojoScore_3735226.png",
        "date": "2025-11-28 10:05:12",
        "description": "Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. This adjustment highlights evolving perspectives on the company’s valuation, financial trends, quality metrics, and technical outlook amid a backdrop of mixed performance indicators."
      },
      {
        "title": "Gujarat Themis Biosyn Sees Shift in Technical Momentum Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gujarat-themis-biosyn-sees-technical-momentum-shift-amid-mixed-market-signals-3719725",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratThemisBi_technicaldot_3719725.png",
        "date": "2025-11-21 08:07:35",
        "description": "Gujarat Themis Biosyn, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across various timeframes. Recent market data reveals a mild adjustment in the company’s technical parameters, coinciding with a day change of -3.73% and a current price of ₹420.75, down from the previous close of ₹437.05."
      },
      {
        "title": "How has been the historical performance of Guj. Themis Bio.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-themis-bio-3694048",
        "imagepath": "",
        "date": "2025-11-12 23:18:30",
        "description": "Answer:\nThe historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years.\n\nBreakdown:\nGuj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'..."
      },
      {
        "title": "Are Guj. Themis Bio. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-guj-themis-bio-latest-results-good-or-bad-3690488",
        "imagepath": "",
        "date": "2025-11-11 19:35:27",
        "description": "Gujarat Themis Biosyn's latest financial results for Q2 FY26 highlight a notable performance across several key metrics. The company reported net sales of ₹42.35 crores, reflecting an 18.07% quarter-on-quarter growth and a robust 21.98% increase year-on-year. This marks the highest quarterly sales figure in the company's recent history. The operating profit margin, excluding other income, reached a record 49.47%, indicating strong cost management and pricing power.\n\nNet profit for the quarter stood at ₹14.26 crores, which represents a significant 57.40% increase compared to the previous quarter. The net profit margin improved to 33.67%, showcasing effective operational leverage and tax management. These results are particularly impressive given the broader challenges faced by the pharmaceutical sector, which has seen negative returns over the past year.\n\nThe company also demonstrated exceptional capital eff..."
      },
      {
        "title": "Gujarat Themis Biosyn Reports Significant Financial Improvements and Market Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gujarat-themis-biosyns-financial-trend-shifts-from-negative-to-positive-with-strong-performance-3687903",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratThemisBi_fintrenddot_3687903.png",
        "date": "2025-11-11 08:00:23",
        "description": "Gujarat Themis Biosyn has reported significant financial improvements for the quarter ending September 2025, achieving record net sales of Rs 42.35 crore and a PBDIT of Rs 20.95 crore. The company also demonstrated strong operational efficiency with a 49.47% operating profit margin and impressive profitability metrics."
      },
      {
        "title": "Gujarat Themis Biosyn Q2 FY26: Stellar Quarter Pushes Stock to New Heights",
        "link": "https://www.marketsmojo.com/news/result-analysis/gujarat-themis-biosyn-q2-fy26-stellar-quarter-pushes-stock-to-new-heights-3686716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratThemisBi_quaterlyResult_3686716.png",
        "date": "2025-11-10 18:06:28",
        "description": "Gujarat Themis Biosyn Ltd., a Vapi-based pharmaceutical manufacturer, delivered an exceptional performance in Q2 FY26, posting net profit of ₹14.26 crores—a 34.92% quarter-on-quarter surge and 21.98% year-on-year growth. The company's shares have responded enthusiastically, trading at ₹454.25 as of November 10, representing a 0.89% single-day gain and maintaining a commanding 40.20% annual return despite the stock's premium valuation of 111 times trailing earnings."
      },
      {
        "title": "Gujarat Themis Biosyn Hits New 52-Week High of Rs. 468.95",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gujarat-themis-biosyn-hits-new-52-week-high-of-rs-46895-3648328",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/GujaratThemisBi_priceRelatedfactors_3648328.png",
        "date": "2025-10-27 11:18:51",
        "description": "Gujarat Themis Biosyn has achieved a new 52-week high, reflecting its strong position in the pharmaceuticals and biotechnology sector. The stock has shown consistent upward momentum, trading above key moving averages. In the broader market, the Sensex is also experiencing positive trends, with mega-cap stocks driving gains."
      }
    ],
    "total": 336,
    "sid": "925632",
    "stock_news_url": "https://www.marketsmojo.com/news/gujarat-themis-biosyn-925632"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "11-Nov-2025",
      "details": "Newspaper publication of un-audited financial results for the quarter and half year ended 30th September2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "10-Nov-2025",
      "details": "Please refer to the attachment.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "10-Nov-2025",
      "details": "Investor Presentation for the quarter ended 30.09.2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Gujarat Themis Biosyn Ltd has declared <strong>67%</strong> dividend, ex-date: 04 Sep 25",
          "dt": "2025-09-04",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Gujarat Themis Biosyn Ltd has announced <strong>1:5</strong> stock split, ex-date: 10 Oct 23",
          "dt": "2023-10-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Gujarat Themis Biosyn Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 09 Aug 24",
          "dt": "2024-08-09",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Guj. Themis Bio. falling/rising?

2025-12-20 02:24:50

Stock Performance Outshines Benchmarks

The recent price surge is underpinned by the company’s impressive track record relative to broader market indices. Over the past year, Gujarat Themis Biosyn has delivered a 32.00% return, significantly outperforming the Sensex’s 7.21% gain during the same period. Even more striking is the stock’s five-year return of 1087.67%, dwarfing the Sensex’s 80.85% growth. This exceptional long-term performance highlights the company’s ability to generate substantial shareholder value, which continues to attract investor confidence.

In the short term, the stock has also shown resilience. Despite a one-month dip of 6.52%, it rebounded strongly in the past week with a 4.22% gain, while the Sensex declined by 0.40%. This recent recovery signals...

Guj. Themis Bio. Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-12-19 10:10:20

Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, highlighting both strengths and challenges in its recent performance.

Guj. Themis Bio. Sees Revision in Market Assessment Amid Valuation and Financial Trends

2025-11-28 10:05:12

Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. This adjustment highlights evolving perspectives on the company’s valuation, financial trends, quality metrics, and technical outlook amid a backdrop of mixed performance indicators.

Gujarat Themis Biosyn Sees Shift in Technical Momentum Amid Mixed Market Signals

2025-11-21 08:07:35

Gujarat Themis Biosyn, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across various timeframes. Recent market data reveals a mild adjustment in the company’s technical parameters, coinciding with a day change of -3.73% and a current price of ₹420.75, down from the previous close of ₹437.05.

How has been the historical performance of Guj. Themis Bio.?

2025-11-12 23:18:30

Answer: The historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years. Breakdown: Guj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'...

Are Guj. Themis Bio. latest results good or bad?

2025-11-11 19:35:27

Gujarat Themis Biosyn's latest financial results for Q2 FY26 highlight a notable performance across several key metrics. The company reported net sales of ₹42.35 crores, reflecting an 18.07% quarter-on-quarter growth and a robust 21.98% increase year-on-year. This marks the highest quarterly sales figure in the company's recent history. The operating profit margin, excluding other income, reached a record 49.47%, indicating strong cost management and pricing power. Net profit for the quarter stood at ₹14.26 crores, which represents a significant 57.40% increase compared to the previous quarter. The net profit margin improved to 33.67%, showcasing effective operational leverage and tax management. These results are particularly impressive given the broader challenges faced by the pharmaceutical sector, which has seen negative returns over the past year. The company also demonstrated exceptional capital eff...

Gujarat Themis Biosyn Reports Significant Financial Improvements and Market Outperformance

2025-11-11 08:00:23

Gujarat Themis Biosyn has reported significant financial improvements for the quarter ending September 2025, achieving record net sales of Rs 42.35 crore and a PBDIT of Rs 20.95 crore. The company also demonstrated strong operational efficiency with a 49.47% operating profit margin and impressive profitability metrics.

Gujarat Themis Biosyn Q2 FY26: Stellar Quarter Pushes Stock to New Heights

2025-11-10 18:06:28

Gujarat Themis Biosyn Ltd., a Vapi-based pharmaceutical manufacturer, delivered an exceptional performance in Q2 FY26, posting net profit of ₹14.26 crores—a 34.92% quarter-on-quarter surge and 21.98% year-on-year growth. The company's shares have responded enthusiastically, trading at ₹454.25 as of November 10, representing a 0.89% single-day gain and maintaining a commanding 40.20% annual return despite the stock's premium valuation of 111 times trailing earnings.

Gujarat Themis Biosyn Hits New 52-Week High of Rs. 468.95

2025-10-27 11:18:51

Gujarat Themis Biosyn has achieved a new 52-week high, reflecting its strong position in the pharmaceuticals and biotechnology sector. The stock has shown consistent upward momentum, trading above key moving averages. In the broader market, the Sensex is also experiencing positive trends, with mega-cap stocks driving gains.